Navigation Links
BioMolecular Therapeutics, a New Global Player in RNAi Therapeutics, Launches Company and Adds Key Advisors
Date:10/19/2010

SEOUL, South Korea, Oct. 19 /PRNewswire/ -- BioMolecular Therapeutics, Inc. (BMT, Inc.), a new Seoul-based RNAi therapeutics company with a proprietary technology designed to reduce significantly deleterious side effects triggered by conventional siRNA, announced that it has launched its global operations. The company is currently developing a novel RNAi therapeutic for age-related macular degeneration (AMD), based on its asymmetric shorter-duplex siRNA (asiRNA) technology, originally published in Molecular Therapy in 2009 as a featured article. Early studies suggest that the asiRNA technology will allow the application of RNAi therapeutics in fields where innate immune stimulation needs to be avoided, such as AMD. The goal of an RNAi therapeutic is to target specifically only the gene or genes implicated in the disease. In AMD, activation of the innate immune response could elicit off-target effects, potentially hastening the progression of the disease. Two previous clinical trials using traditional siRNA as an AMD therapeutic were terminated at Phase II and III because of unintended activation of the patients' immune response.

BMT's leadership team includes Dong-ki Lee, Ph.D., the inventor of the company's proprietary technology, and Sun woo Hong, Ph.D., BMT's founding CEO. Dr. Dong-ki Lee is associate professor of chemistry at Sungkyunkwan University in Suwon, Korea, and the recipient of the prestigious Global Research Laboratory grant from the Korean government for the development of novel RNAi therapeutics. Dr. Sun Woo Hong has strong expertise in siRNA and genomics research, and was research professor at Dongguk University in Seoul, Korea. The company has also named two key advisors, Jayakrishna Ambati, M.D., ophthalmologist and professor at University of Kentucky Medical School, and Johannes Fruehauf, M.D., Ph.D., an experienced biotechnology executive and a specialist in RNAi therapeutics.  

Dr. Ambati will serve as head of BMT's scientific advisory board. He is an authority in ophthalmology and well-known for his seminal contributions in macular degeneration research. His lab made numerous foundational discoveries published in Nature, Nature Medicine, PNAS, and the Journal of Clinical Investigation; these include exceptional findings about the role of the innate immune system in the mechanisms and treatment of AMD. Dr. Ambati won the 2010 Cogan Award from The Association for Research in Vision and Ophthalmology (ARVO) for his contributions in macular degeneration research. "We are extremely honored that Dr. Ambati has agreed to join BMT as chair of our scientific advisory board," said BMT CEO, Sun Woo Hong. "He brings unparalleled expertise and experience in eye disease research, an area so fundamental to our success. We expect that the addition of his expertise will accelerate and strengthen our progress to develop RNAi therapeutics for AMD using our proprietary asiRNA platform."

Dr. Fruehauf has been appointed as the first external director to BMT's board. He is currently vice president of R&D at Aura Biosciences, and founder and president of ViThera Laboratories. Previously, he was a cofounder and VP of research at Cequent Pharmaceuticals, now Marina Biotech, where he oversaw the development from bench into clinical trials of the first oral RNAi therapeutic, CEQ508. Dr. Dong-ki Lee commented, "With Dr. Fruehauf joining our board, we are entering the next phase of BMT's growth. His expertise in building and managing early-stage biotech startup companies and achieving scientific progress towards key milestones is invaluable for our next steps: establishing business relationships and scientific alliances in the United States, and internationally."

The company is making its inaugural U.S. poster presentation at the 6th Annual Meeting of the Oligonucleotide Therapeutics Society, which begins tomorrow in Dana Point, California. The title is Reduced Innate Immune Stimulation by asiRNA Structure: Expanding Therapeutic Application of siRNA.

About Age-Related Macular Degeneration (AMD)

A leading cause of vision loss and blindness, AMD is a disease associated with aging that gradually destroys sharp, central vision. According to the National Eye Institute, age-related macular degeneration affects more than 1.75 million individuals in the United States alone. This number is expected to increase to almost three million by 2020.

About BioMolecular Therapeutics, Inc. (www.bmtlab.co.kr)

An early-stage biopharmaceutical company, BMT is pioneering the development of novel RNAi therapeutics to prevent and treat age-related macular degeneration based on the company's proprietary technology, asymmetric shorter-duplex siRNA (asiRNA). This novel RNAi technology significantly reduces deleterious side effects triggered by conventional siRNA, especially, the stimulation of the innate immune system, which makes it feasible to use asiRNA for the treatment of age-related macular degeneration, a disease to which RNAi therapeutics could not be developed using conventional siRNAs. Other potential applications for BMT's technology include therapeutics targeting infectious disease, such as herpes simplex virus (HSV), and cancer. A privately held company based in Suwon, South Korea, BMT was established in 2010.


'/>"/>
SOURCE BioMolecular Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, https://wcg.swoogo.com/modern-sop-and-quality-systems , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):